PL2429317T5 - Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego - Google Patents
Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowegoInfo
- Publication number
- PL2429317T5 PL2429317T5 PL09776547T PL09776547T PL2429317T5 PL 2429317 T5 PL2429317 T5 PL 2429317T5 PL 09776547 T PL09776547 T PL 09776547T PL 09776547 T PL09776547 T PL 09776547T PL 2429317 T5 PL2429317 T5 PL 2429317T5
- Authority
- PL
- Poland
- Prior art keywords
- omega
- fatty acids
- low content
- phytanic acid
- compositions rich
- Prior art date
Links
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 title 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 title 1
- 229940012843 omega-3 fatty acid Drugs 0.000 title 1
- 239000006014 omega-3 oil Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/08—Refining
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09776547.3A EP2429317B2 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
PCT/EP2009/002842 WO2010118761A1 (en) | 2009-04-17 | 2009-04-17 | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2429317T3 PL2429317T3 (pl) | 2016-09-30 |
PL2429317T5 true PL2429317T5 (pl) | 2019-09-30 |
Family
ID=41279300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09776547T PL2429317T5 (pl) | 2009-04-17 | 2009-04-17 | Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego |
Country Status (14)
Country | Link |
---|---|
US (1) | US9062275B2 (pl) |
EP (1) | EP2429317B2 (pl) |
JP (1) | JP5872453B2 (pl) |
KR (1) | KR101759353B1 (pl) |
CN (1) | CN102438468B (pl) |
AU (1) | AU2009344374B2 (pl) |
BR (1) | BRPI0924012A2 (pl) |
CA (1) | CA2756528A1 (pl) |
DK (1) | DK2429317T4 (pl) |
ES (1) | ES2574136T5 (pl) |
MX (1) | MX2011010821A (pl) |
PL (1) | PL2429317T5 (pl) |
PT (1) | PT2429317T (pl) |
WO (1) | WO2010118761A1 (pl) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130245119A1 (en) * | 2010-11-19 | 2013-09-19 | Keio University | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders |
CA2825022A1 (en) * | 2011-01-25 | 2012-08-02 | Nestec S.A. | Methods and compositions for treating, reducing, or preventing deterioration of the visual system of animals |
US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
CN102747045B (zh) * | 2011-04-19 | 2013-12-18 | 华中农业大学 | 一种猪流感h1n1亚型灭活疫苗及制备方法 |
CA2845868C (en) | 2011-09-12 | 2018-11-06 | Tassos GEORGIOU | Use of epa and dha in treating occular disorder |
EP3348262A1 (en) | 2012-01-06 | 2018-07-18 | Omthera Pharmaceuticals Inc. | Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
MY189576A (en) | 2012-03-30 | 2022-02-17 | Micelle Biopharma Inc | Omega-3 fatty acid ester compositions |
JP6173437B2 (ja) | 2012-05-07 | 2017-08-02 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | スタチン及びω−3脂肪酸の組成物 |
ES2621226T3 (es) * | 2012-09-12 | 2017-07-03 | Novaliq Gmbh | Composiciones de alcanos semifluorados |
EP3100722B1 (en) | 2012-09-12 | 2024-03-20 | Novaliq GmbH | Semifluorinated alkanes for use in solubilizing meibum |
US9719970B2 (en) | 2012-11-30 | 2017-08-01 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin D metabolites |
ITMI20130354A1 (it) | 2013-03-08 | 2014-09-09 | Again Life Italia Srl | Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie. |
US20160029919A1 (en) | 2013-03-14 | 2016-02-04 | UNIVERSITé LAVAL | Use of electroretinography (erg) for the assessment of psychiatric disorders |
EP2968147A4 (en) * | 2013-03-15 | 2017-02-22 | The Penn State Research Foundation | Acid stable liposomal compositions |
JP6495245B2 (ja) * | 2013-04-22 | 2019-04-03 | スマートフィッシュ・アーエス | がんの治療及び/又は後治療のための魚油及びジュースを含む組成物の使用 |
CN105658215A (zh) * | 2013-10-28 | 2016-06-08 | 雀巢产品技术援助有限公司 | 用于治疗具有非机械基础的吸收不良的单酰基甘油和脂溶性营养物质 |
EP2881456A1 (en) | 2013-12-04 | 2015-06-10 | Natac Pharma, S.L. | Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid |
CN105828813A (zh) * | 2013-12-19 | 2016-08-03 | 塔索斯·乔治奥 | 涉及治疗神经***损伤的疾病的ω3脂肪酸组合物 |
ES2889874T3 (es) * | 2014-03-13 | 2022-01-14 | Retrotope Inc | Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas |
WO2015165507A1 (en) * | 2014-04-29 | 2015-11-05 | Georgiou Tassos | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio |
JP2016141624A (ja) * | 2015-01-30 | 2016-08-08 | 有限会社ハヌマット | 癌患者の予後改善剤 |
US10821090B2 (en) | 2015-03-26 | 2020-11-03 | Tiberio Bruzzese | Purified compositions of polyunsaturated fatty acids, their preparation method and their use |
WO2017038861A1 (ja) | 2015-08-31 | 2017-03-09 | 日本水産株式会社 | 遊離多価不飽和脂肪酸含有組成物及びその製造方法 |
EP3385359A4 (en) * | 2015-12-01 | 2019-07-24 | Nippon Suisan Kaisha, Ltd. | DOCOSAHEXAIC ACID-CONTAINING OIL AND METHOD FOR THE PRODUCTION THEREOF |
CN109073648A (zh) * | 2016-03-15 | 2018-12-21 | 拜尔梅里科有限公司 | 纤维肌痛敏感测试的组合物、设备以及方法 |
KR20180051737A (ko) * | 2016-11-08 | 2018-05-17 | 차의과학대학교 산학협력단 | 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물 |
RU2652342C1 (ru) * | 2017-07-13 | 2018-04-25 | Наталья Александровна Гаврилова | Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
CN108096181A (zh) * | 2018-02-05 | 2018-06-01 | 西安医学院 | Dha、epa在制备治疗干眼症的口服药物的应用 |
KR20210016746A (ko) | 2019-08-05 | 2021-02-17 | 충남대학교산학협력단 | 오메가-3 불포화 지방산을 포함하는 항톡소포자충 조성물 |
EP4017484A4 (en) * | 2019-08-21 | 2022-10-19 | Burke & Boyer, Inc. | MONO-UNSATURATED FATTY ACID COMPOSITION AND THEIR USE FOR THE TREATMENT OF HEPATIC STEATOSIS |
CN110846346B (zh) * | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | 富含Sn-2位DHA的微生物油脂及其制备方法和应用 |
KR20210018171A (ko) | 2020-11-16 | 2021-02-17 | 충남대학교산학협력단 | 오메가-3 지방산으로의 전환을 유도하는 Caenorhabditis elegans fat-1효소를 포함하는 항톡소포자충 조성물 |
CN113584093B (zh) * | 2021-07-30 | 2022-07-19 | 江南大学 | 一种高dha含量的结构脂质的制备方法及其产品 |
CN113995747A (zh) * | 2021-10-19 | 2022-02-01 | 杭州莱樱斯生物医药科技有限公司 | 一种治疗脱发的产品及银杏内酯a在治疗应激诱发脱发的新用途 |
KR20240094157A (ko) | 2022-12-13 | 2024-06-25 | 충남대학교산학협력단 | 노빌레틴을 유효성분으로 하는 톡소포자충 감염증의 예방 또는 치료용 조성물 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5697503A (en) * | 1980-01-07 | 1981-08-06 | Nippon Oil & Fats Co Ltd | Separation of constituent component from mixed composition of plural component of org. compound |
JPS57149400A (en) * | 1981-03-12 | 1982-09-14 | Kureha Chemical Ind Co Ltd | Manufacture of high purity long chain highly unsaturated fatty acid ester |
EP0347509A1 (en) | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | A process of extraction and purification of polyunsaturated fatty acids from natural sources |
US4792418A (en) * | 1985-08-14 | 1988-12-20 | Century Laboratories, Inc. | Method of extraction and purification of polyunsaturated fatty acids from natural sources |
IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
US5023100A (en) | 1988-05-02 | 1991-06-11 | Kabi Vitrum Ab | Fish oil |
US4874629A (en) | 1988-05-02 | 1989-10-17 | Chang Stephen S | Purification of fish oil |
JPH0225447A (ja) * | 1988-07-13 | 1990-01-26 | Nippon Oil & Fats Co Ltd | 高度不飽和脂肪酸類の製造方法 |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
DK190689D0 (da) | 1989-04-19 | 1989-04-19 | Novo Industri As | Omestringsproces |
US5013569A (en) | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
SE9303446D0 (sv) | 1993-10-20 | 1993-10-20 | Trikonex Ab | A novel urea fractionation process |
CN1105205A (zh) | 1994-01-11 | 1995-07-19 | 黄升 | 富含dha和活性钙的补脑益智营养食品及其制备方法 |
ES2131129T3 (es) | 1994-05-09 | 1999-07-16 | Nestle Sa | Procedimiento para la preparacion de un concentrado de esteres de acidos grasos poliinsaturados. |
JPH0898659A (ja) | 1994-09-30 | 1996-04-16 | Nippon Suisan Kaisha Ltd | ストレスに対する改善効果を有する魚類用飼料 |
CN1130040A (zh) | 1995-12-05 | 1996-09-04 | 杨学斌 | 一种含dha的健脑膨化食品 |
GB2350610A (en) | 1999-06-01 | 2000-12-06 | Jfs Envirohealth Ltd | Preparation of pure unsaturated fatty acids |
CA2311974A1 (en) | 1999-06-28 | 2000-12-28 | Nisshin Flour Milling Co., Ltd. | Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
JP4530311B2 (ja) † | 2000-07-13 | 2010-08-25 | 日本水産株式会社 | リパーゼを用いたグリセライドの製造方法 |
CN1345544A (zh) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | 海洋产物营养保健蛋的生产方法 |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
CN1378846A (zh) * | 2002-03-22 | 2002-11-13 | 海南加华海产生物制药有限公司 | 鲨鱼肝油胶丸 |
EP1542670B2 (en) * | 2002-09-24 | 2023-07-05 | Suntory Holdings Limited | Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults |
US6846942B2 (en) | 2003-05-20 | 2005-01-25 | David Rubin | Method for preparing pure EPA and pure DHA |
CN1245169C (zh) | 2004-01-29 | 2006-03-15 | 任连坤 | 一种提高记忆力、改善认知的纯天然复合制剂及其制备方法 |
CN101018862B (zh) * | 2004-04-22 | 2013-10-09 | 联邦科学技术研究组织 | 用重组细胞合成长链多不饱和脂肪酸 |
KR20070090928A (ko) * | 2004-11-19 | 2007-09-06 | 마텍 바이오싸이언스스 코포레이션 | 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법 |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
CN103211807A (zh) * | 2005-07-08 | 2013-07-24 | Dsmip资产公司 | 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸 |
ITMI20051560A1 (it) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
WO2007071733A2 (en) * | 2005-12-21 | 2007-06-28 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
US20070213298A1 (en) * | 2006-02-07 | 2007-09-13 | Universitetet I Oslo | Omega 3 |
US8003813B2 (en) * | 2006-06-27 | 2011-08-23 | Pos Pilot Plant Corporation | Process for separating saturated and unsaturated fatty acids |
US7550614B2 (en) | 2006-11-13 | 2009-06-23 | Rohm And Haas Company | Method for esterification of free fatty acids in triglycerides |
KR100832397B1 (ko) * | 2007-02-12 | 2008-05-26 | 경북대학교 산학협력단 | 디아실글리세롤함유 식용유지의 제조방법 |
CN100574772C (zh) * | 2007-03-23 | 2009-12-30 | 童宥霖 | 一种含叶黄素的软胶囊及其制备方法 |
US20080268117A1 (en) | 2007-04-30 | 2008-10-30 | David Rubin | Method of purifying oils containing epa and dha |
WO2009020406A1 (en) * | 2007-08-07 | 2009-02-12 | Granate Seed Limited | Methods of making lipid substances, lipid substances made thereby and uses thereof |
CN101381298B (zh) * | 2008-10-21 | 2011-09-07 | 四川省毛叶山桐子科技股份有限公司 | 利用毛叶山桐子油制备共轭亚油酸的方法 |
WO2011018096A1 (en) * | 2009-08-10 | 2011-02-17 | K.D. Pharma Bexbach Gmbh | Phytanic acid fractionation process, fatty acid products and use thereof |
-
2009
- 2009-04-17 PT PT97765473T patent/PT2429317T/pt unknown
- 2009-04-17 MX MX2011010821A patent/MX2011010821A/es active IP Right Grant
- 2009-04-17 BR BRPI0924012A patent/BRPI0924012A2/pt not_active IP Right Cessation
- 2009-04-17 WO PCT/EP2009/002842 patent/WO2010118761A1/en active Application Filing
- 2009-04-17 DK DK09776547.3T patent/DK2429317T4/da active
- 2009-04-17 ES ES09776547T patent/ES2574136T5/es active Active
- 2009-04-17 CA CA2756528A patent/CA2756528A1/en not_active Abandoned
- 2009-04-17 JP JP2012505054A patent/JP5872453B2/ja active Active
- 2009-04-17 KR KR1020117027108A patent/KR101759353B1/ko active IP Right Grant
- 2009-04-17 CN CN200980158786.7A patent/CN102438468B/zh active Active
- 2009-04-17 AU AU2009344374A patent/AU2009344374B2/en active Active
- 2009-04-17 US US13/264,659 patent/US9062275B2/en active Active
- 2009-04-17 EP EP09776547.3A patent/EP2429317B2/en active Active
- 2009-04-17 PL PL09776547T patent/PL2429317T5/pl unknown
Also Published As
Publication number | Publication date |
---|---|
PL2429317T3 (pl) | 2016-09-30 |
WO2010118761A1 (en) | 2010-10-21 |
ES2574136T5 (es) | 2019-08-30 |
CN102438468A (zh) | 2012-05-02 |
BRPI0924012A2 (pt) | 2019-09-24 |
EP2429317B2 (en) | 2019-02-20 |
EP2429317A1 (en) | 2012-03-21 |
DK2429317T4 (da) | 2019-05-13 |
ES2574136T3 (es) | 2016-06-15 |
JP2012523823A (ja) | 2012-10-11 |
AU2009344374B2 (en) | 2015-07-23 |
DK2429317T3 (en) | 2016-07-18 |
US9062275B2 (en) | 2015-06-23 |
KR101759353B1 (ko) | 2017-07-18 |
MX2011010821A (es) | 2012-01-20 |
JP5872453B2 (ja) | 2016-03-01 |
EP2429317B1 (en) | 2016-03-30 |
CN102438468B (zh) | 2014-06-04 |
KR20120039521A (ko) | 2012-04-25 |
PT2429317T (pt) | 2016-07-22 |
US20120053242A1 (en) | 2012-03-01 |
CA2756528A1 (en) | 2010-10-21 |
AU2009344374A1 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2429317T3 (pl) | Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego | |
IL266231A (en) | Omega-3 polyunsaturated fatty acid compounds enriched in dpa in the form of a free acid phase fat | |
HK1198544A1 (en) | Microbial oils enriched in polyunsaturated fatty acids | |
IL215827A0 (en) | Omega-3 fatty acid enriched beverages | |
IL249821A0 (en) | Preparations of omega 3 fatty acid esters | |
EP2173184A4 (en) | OMEGA TYPE ENRICHED FATTY ACID COMPOSITION | |
IL212112A0 (en) | Production of modifird fatty acids in plants | |
ZA201109067B (en) | Acyltransferases and uses thereof in fatty acid production | |
EP2459189A4 (en) | FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES | |
PL2234994T3 (pl) | Mieszanki estrów butylowych kwasów tłuszczowych | |
IL215828A0 (en) | Omega-3 fatty acid enriched baked foods and bar compositions | |
IL214887A0 (en) | Fatty acid monoglyceride compositions | |
ZA201302760B (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
IL219958A0 (en) | Omega-3 fatty acid enriched meat compositions | |
HK1170169A1 (en) | Pharmaceutical composition including a dha ester to be parenterally administered dha | |
HK1185806A1 (zh) | 含有多不飽和脂肪酸的組合物 | |
GB0904300D0 (en) | Essential fatty acid compounds | |
PL2550345T3 (pl) | Podpałka na bazie estru kwasu tłuszczowego |